miR‑22‑3p enhances multi‑chemoresistance by targeting NET1 in bladder cancer cells

Xiao,Jun; Niu,Sanqiang; Zhu,Jiahong; Lv,Lei; Deng,Hui; Pan,Daqing; Shen,Deyun; Xu,Congyun; Shen,Zhou; Tao,Tao

doi:10.3892/or.2018.6355

miR‑22‑3p enhances multi‑chemoresistance by targeting NET1 in bladder cancer cells

Authors:
- Jun Xiao
- Sanqiang Niu
- Jiahong Zhu
- Lei Lv
- Hui Deng
- Daqing Pan
- Deyun Shen
- Congyun Xu
- Zhou Shen
- Tao Tao
View Affiliations

Affiliations: Department of Urology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230001, P.R. China, Department of Urology, Bozhou People's Hospital, Bozhou, Anhui 236800, P.R. China, Cancer Epigenetics Program, Anhui Cancer Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230031, P.R. China
Published online on: April 4, 2018 https://doi.org/10.3892/or.2018.6355
Pages: 2731-2740

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

With the discovery of new chemotherapeutic drugs, chemotherapy becomes increasingly valuable. However, the resistance of tumor cells to chemotherapeutic agents significantly limits the effectiveness and causes chemotherapy failure. MicroRNAs have been shown to regulate drug resistance in many types of cancer. In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita‑Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H‑bc) and conducted a multi‑group test. This test included expression group analyses of coding and non‑coding genes (miR‑omic and RNA‑seq). Based on our analyses, we selected miR‑22‑3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan‑quantitative reverse transcription polymerase chain reaction (qRT‑PCR), western blot analysis and luciferase reporter assay. The effect of miR‑22‑3p on BCa multi‑chemoresistance was also determined by transfecting cells with the miR‑22‑3p‑mimic or miR‑22‑3p‑antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA‑mediated NET1 inhibition or pINDUCER21‑enhanced green fluorescent protein‑NET1‑mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR‑22‑3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR‑22‑3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Chang JS, Lara PN Jr and Pan CX: Progress in personalizing chemotherapy for bladder cancer. Adv Urol. 2012:3649192012. View Article : Google Scholar : PubMed/NCBI
3	Bambury RM, Power DG and O'Reilly S: Intratumor heterogeneity and branched evolution. N Engl J Med. 366:2132–2133. 2012. View Article : Google Scholar : PubMed/NCBI
4	Setoyama T, Ling H, Natsugoe S and Calin GA: Non-coding RNAs for medical practice in oncology. Keio J Med. 60:106–113. 2011. View Article : Google Scholar : PubMed/NCBI
5	Chan B, Manley J, Lee J and Singh SR: The emerging roles of microRNAs in cancer metabolism. Cancer Lett. 356:301–308. 2015. View Article : Google Scholar : PubMed/NCBI
6	Allen KE and Weiss GJ: Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 9:3126–3136. 2010. View Article : Google Scholar : PubMed/NCBI
7	Vinall RL, Ripoll AZ, Wang S, Pan CX and deVere White RW: MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer. 130:2526–2538. 2012. View Article : Google Scholar : PubMed/NCBI
8	Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, Wang M, Zhang Z and Zhang W: microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep. 25:1721–1729. 2011.PubMed/NCBI
9	Su SF, Chang YW, Andreu-Vieyra C, Fang JY, Yang Z, Han B, Lee AS and Liang G: miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene. 32:4694–4701. 2013. View Article : Google Scholar : PubMed/NCBI
10	Lv L, Li Y, Deng H, Zhang C, Pu Y, Qian L, Xiao J, Zhao W, Liu Q, Zhang D, et al: MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett. 357:105–113. 2015. View Article : Google Scholar : PubMed/NCBI
11	Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, Xiao J, Qian L, Zhao W, Liu Q, et al: The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer. Biochim Biophys Acta. 1852:520–528. 2015. View Article : Google Scholar : PubMed/NCBI
12	Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, Xiao J, Qian L, Zhao W, Liu Q, et al: miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway. Mol Cancer. 13:2342014. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Deng H, Lv L, Zhang C, Qian L, Xiao J, Zhao W, Liu Q, Zhang D, Wang Y, et al: The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. Oncotarget. 6:10195–10206. 2015.PubMed/NCBI
14	Gurha P, Abreu-Goodger C, Wang T, RamiRez MO, Drumond AL, van Dongen S, Chen Y, Bartonicek N, Enright AJ, Lee B, et al: Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation. 125:2751–2761. 2012. View Article : Google Scholar : PubMed/NCBI
15	Li C, Ni J, Liu YX, Wang H, Liang ZQ and Wang X: Response of MiRNA-22-3p and MiRNA-149-5p to folate deficiency and the differential regulation of MTHFR expression in normal and cancerous human hepatocytes. PLoS One. 12:e01680492017. View Article : Google Scholar : PubMed/NCBI
16	Wang X, Yu H, Lu X, Zhang P, Wang M and Hu Y: MiR-22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. Biochem Biophys Res Commun. 445:175–179. 2014. View Article : Google Scholar : PubMed/NCBI
17	Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, et al: MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell. 154:311–324. 2013. View Article : Google Scholar : PubMed/NCBI
18	Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM, Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J, Avigan DE, et al: The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell. 13:87–101. 2013. View Article : Google Scholar : PubMed/NCBI
19	Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, et al: Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 3:ra292010. View Article : Google Scholar : PubMed/NCBI
20	Luo LJ, Zhang LP, Duan CY, Wang B, He NN, Abulimiti P and Lin Y: The inhibition role of miR-22 in hepatocellular carcinoma cell migration and invasion via targeting CD147. Cancer Cell Int. 17:172017. View Article : Google Scholar : PubMed/NCBI
21	Parrish JK, Sechler M, Winn RA and Jedlicka P: The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. Oncogene. 34:257–262. 2015. View Article : Google Scholar : PubMed/NCBI
22	Li X, Wang S, Chen Y, Liu G and Yang X: miR-22 targets the 3′UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy. Tumour Biol. 35:6021–6028. 2014. View Article : Google Scholar : PubMed/NCBI
23	Bennett G, Sadlier D, Doran PP, Macmathuna P and Murray DW: A functional and transcriptomic analysis of NET1 bioactivity in gastric cancer. BMC Cancer. 11:502011. View Article : Google Scholar : PubMed/NCBI
24	He S, Wei YZ, Wang GL, Xu YY, Zhou JM, Zhang YX and Chen L: Study of RNA interference targeting NET-1 combination with sorafenib for hepatocellular carcinoma therapy in vitro and in vivo. Gastroenterol Res Pract. 2013:6851502013. View Article : Google Scholar : PubMed/NCBI
25	Ahmad HM, Muiwo P, Ramachandran SS, Pandey P, Gupta YK, Kumar L, Kulshreshtha R and Bhattacharya A: miR-22 regulates expression of oncogenic neuro-epithelial transforming gene 1, NET1. FEBS J. 281:3904–3919. 2014. View Article : Google Scholar : PubMed/NCBI
26	Kaur K, Vig S, Srivastava R, Mishra A, Singh VP, Srivastava AK and Datta M: Elevated hepatic miR-22-3p expression impairs gluconeogenesis by silencing the wnt-responsive transcription factor Tcf7. Diabetes. 64:3659–3669. 2015. View Article : Google Scholar : PubMed/NCBI
27	Gu W, Zhan H, Zhou XY, Yao L, Yan M, Chen A, Liu J, Ren X, Zhang X, Liu JX and Liu G: MicroRNA-22 regulates inflammation and angiogenesis via targeting VE-cadherin. FEBS Lett. 591:513–526. 2017. View Article : Google Scholar : PubMed/NCBI
28	Hong Y, Cao H, Wang Q, Ye J, Sui L, Feng J, Cai X, Song H, Zhang X and Chen X: MiR-22 may suppress fibrogenesis by targeting TGFbetaR I in cardiac fibroblasts. Cell Physiol Biochem. 40:1345–1353. 2016. View Article : Google Scholar : PubMed/NCBI
29	Chen J, Wu FX, Luo HL, Liu JJ, Luo T, Bai T, Li LQ and Fan XH: Berberine upregulates miR-22-3p to suppress hepatocellular carcinoma cell proliferation by targeting Sp1. Am J Transl Res. 8:4932–4941. 2016.PubMed/NCBI
30	Xu D, Guo Y, Liu T, Li S and Sun Y: miR-22 contributes to endosulfan-induced endothelial dysfunction by targeting SRF in HUVECs. Toxicol Lett. 269:33–40. 2017. View Article : Google Scholar : PubMed/NCBI
31	Zhang J, Fei B, Wang Q, Song M, Yin Y, Zhang B, Ni S, Guo W, Bian Z, Quan C, et al: MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma. Oncotarget. 5:12083–12096. 2014.PubMed/NCBI
32	Lu Z, Luo T, Nie M, Pang T, Zhang X, Shen X, Ma L, Bi J, Wei G, Fang G and Xue X: TSPAN1 functions as an oncogene in gastric cancer and is downregulated by miR-573. FEBS Lett. 589:1988–1994. 2015. View Article : Google Scholar : PubMed/NCBI
33	Serru V, Dessen P, Boucheix C and Rubinstein E: Sequence and expression of seven new tetraspans. Biochim Biophys Acta. 1478:159–163. 2000. View Article : Google Scholar : PubMed/NCBI
34	Todres E, Nardi JB and Robertson HM: The tetraspanin superfamily in insects. Insect Mol Biol. 9:581–590. 2000. View Article : Google Scholar : PubMed/NCBI
35	Ye K, Chang S, Li J, Li X, Zhou Y and Wang Z: A functional and protein-protein interaction analysis of neuroepithelial cell transforming gene 1 in hepatocellular carcinoma. Tumour Biol. 35:11219–11227. 2014. View Article : Google Scholar : PubMed/NCBI
36	zhang J, Wang J, Chen L, Wang G, Qin J, Xu Y and Li X: Expression and function of NET-1 in human skin squamous cell carcinoma. Arch Dermatol Res. 306:385–397. 2014. View Article : Google Scholar : PubMed/NCBI
37	Ecimovic P, Murray D, Doran P and Buggy DJ: Propofol and bupivacaine in breast cancer cell function in vitro-role of the NET1 gene. Anticancer Res. 34:1321–1331. 2014.PubMed/NCBI
38	Fang L, Zhu J, Ma Y, Hong C, Xiao S and Jin L: Neuroepithelial transforming gene 1 functions as a potential prognostic marker for patients with non-small cell lung cancer. Mol Med Rep. 12:7439–7446. 2015. View Article : Google Scholar : PubMed/NCBI